Immuneering (US:IMRX) Globenewswire·2026-01-07 21:00Core Insights - Immuneering Corporation announced positive overall survival (OS) and safety data from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer patients, showing a 64% OS at 12 months [1][2][6] Clinical Trial Results - The trial involved 34 patients with a median follow-up of over 13 months, with the median OS not yet reached as of the data cutoff on December 15, 2025 [6][7] - The OS rates at various time points were significantly higher than the standard of care benchmark from the MPACT study: - 64% at 12 months vs. 35% - 83% at 9 months vs. ~47% - 94% at 6 months vs. 67% [6][7] - The confirmed overall response rate (ORR) was 39% at 12 months compared to 23% for the standard of care, and the disease control rate (DCR) was 81% vs. 48% [6][7] Safety Profile - The combination therapy demonstrated a favorable tolerability profile, with only neutropenia and anemia observed at Grade 3 in more than 10% of patients, which are common with standard chemotherapy [9][11] Future Plans - The company plans to initiate a pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026, with overall survival as the primary endpoint [2][8] - An expanded cohort of over 50 patients is expected to be reported in the first half of 2026, which includes the original 34 patients [10][17] About Atebimetinib - Atebimetinib is a Deep Cyclic Inhibitor targeting MEK, designed to improve durability and tolerability in cancer treatment, particularly for MAPK pathway-driven tumors like pancreatic cancer [13][14]